Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Remon, J., Isla, D., Garrido, P., de Castro, J., Majem, M., Viñolas, N., Artal, A., Carcereny, E., García-Campelo, M. R., Lianes, P., Provencio, M., Juan, O., Diz, P., Blanco, R., Lopez-Castro, R., Maestu, I., Vadell, C., & Felip, E. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 19(12):1537–1542, 2017. doi abstract bibtex BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. CONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.
@article{remon_efficacy_2017,
title = {Efficacy of tyrosine kinase inhibitors in {EGFR}-mutant lung cancer women in a real-world setting: the {WORLD07} database},
volume = {19},
issn = {1699-3055},
shorttitle = {Efficacy of tyrosine kinase inhibitors in {EGFR}-mutant lung cancer women in a real-world setting},
doi = {10.1007/s12094-017-1700-8},
abstract = {BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.
METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.
RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4\% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60\%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.
CONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.},
language = {eng},
number = {12},
journal = {Clinical \& Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
author = {Remon, J. and Isla, D. and Garrido, P. and de Castro, J. and Majem, M. and Viñolas, N. and Artal, A. and Carcereny, E. and García-Campelo, M. R. and Lianes, P. and Provencio, M. and Juan, O. and Diz, P. and Blanco, R. and Lopez-Castro, R. and Maestu, I. and Vadell, C. and Felip, E.},
year = {2017},
pmid = {28660482},
keywords = {Advanced, Article, EGFR mutant, NSCLC, Oncologia, TKI, Women},
pages = {1537--1542},
}
Downloads: 0
{"_id":"r2kDLe35jp88TBLhc","bibbaseid":"remon-isla-garrido-decastro-majem-violas-artal-carcereny-etal-efficacyoftyrosinekinaseinhibitorsinegfrmutantlungcancerwomeninarealworldsettingtheworld07database-2017","downloads":0,"creationDate":"2018-10-11T03:50:31.398Z","title":"Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database","author_short":["Remon, J.","Isla, D.","Garrido, P.","de Castro, J.","Majem, M.","Viñolas, N.","Artal, A.","Carcereny, E.","García-Campelo, M. R.","Lianes, P.","Provencio, M.","Juan, O.","Diz, P.","Blanco, R.","Lopez-Castro, R.","Maestu, I.","Vadell, C.","Felip, E."],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database","volume":"19","issn":"1699-3055","shorttitle":"Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting","doi":"10.1007/s12094-017-1700-8","abstract":"BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. CONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.","language":"eng","number":"12","journal":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","author":[{"propositions":[],"lastnames":["Remon"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Isla"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Garrido"],"firstnames":["P."],"suffixes":[]},{"propositions":["de"],"lastnames":["Castro"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Majem"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Viñolas"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Artal"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Carcereny"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["García-Campelo"],"firstnames":["M.","R."],"suffixes":[]},{"propositions":[],"lastnames":["Lianes"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Provencio"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Juan"],"firstnames":["O."],"suffixes":[]},{"propositions":[],"lastnames":["Diz"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Blanco"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Lopez-Castro"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Maestu"],"firstnames":["I."],"suffixes":[]},{"propositions":[],"lastnames":["Vadell"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Felip"],"firstnames":["E."],"suffixes":[]}],"year":"2017","pmid":"28660482","keywords":"Advanced, Article, EGFR mutant, NSCLC, Oncologia, TKI, Women","pages":"1537–1542","bibtex":"@article{remon_efficacy_2017,\n\ttitle = {Efficacy of tyrosine kinase inhibitors in {EGFR}-mutant lung cancer women in a real-world setting: the {WORLD07} database},\n\tvolume = {19},\n\tissn = {1699-3055},\n\tshorttitle = {Efficacy of tyrosine kinase inhibitors in {EGFR}-mutant lung cancer women in a real-world setting},\n\tdoi = {10.1007/s12094-017-1700-8},\n\tabstract = {BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.\nMETHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.\nRESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4\\% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60\\%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.\nCONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.},\n\tlanguage = {eng},\n\tnumber = {12},\n\tjournal = {Clinical \\& Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},\n\tauthor = {Remon, J. and Isla, D. and Garrido, P. and de Castro, J. and Majem, M. and Viñolas, N. and Artal, A. and Carcereny, E. and García-Campelo, M. R. and Lianes, P. and Provencio, M. and Juan, O. and Diz, P. and Blanco, R. and Lopez-Castro, R. and Maestu, I. and Vadell, C. and Felip, E.},\n\tyear = {2017},\n\tpmid = {28660482},\n\tkeywords = {Advanced, Article, EGFR mutant, NSCLC, Oncologia, TKI, Women},\n\tpages = {1537--1542},\n}\n\n","author_short":["Remon, J.","Isla, D.","Garrido, P.","de Castro, J.","Majem, M.","Viñolas, N.","Artal, A.","Carcereny, E.","García-Campelo, M. R.","Lianes, P.","Provencio, M.","Juan, O.","Diz, P.","Blanco, R.","Lopez-Castro, R.","Maestu, I.","Vadell, C.","Felip, E."],"key":"remon_efficacy_2017","id":"remon_efficacy_2017","bibbaseid":"remon-isla-garrido-decastro-majem-violas-artal-carcereny-etal-efficacyoftyrosinekinaseinhibitorsinegfrmutantlungcancerwomeninarealworldsettingtheworld07database-2017","role":"author","urls":{},"keyword":["Advanced","Article","EGFR mutant","NSCLC","Oncologia","TKI","Women"],"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["efficacy","tyrosine","kinase","inhibitors","egfr","mutant","lung","cancer","women","real","world","setting","world07","database","remon","isla","garrido","de castro","majem","viñolas","artal","carcereny","garcía-campelo","lianes","provencio","juan","diz","blanco","lopez-castro","maestu","vadell","felip"],"keywords":["advanced","article","egfr mutant","nsclc","oncologia","tki","women"],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}